NTAL Phosphorylation is a Pivotal Link Between the Signaling Cascades Leading to Human Mast Cell Degranulation Following Kit Activation and Fc Epsilon RI Aggregation
Overview
Authors
Affiliations
Aggregation of high-affinity receptors for immunoglobulin E (Fc epsilon RI) on the surface of mast cells results in degranulation, a response that is potentiated by binding of stem cell factor (SCF) to its receptor Kit. We observed that one of the major initial signaling events associated with Fc epsilon RI-mediated activation of human mast cells (HuMCs) is the rapid tyrosine phosphorylation of a protein of 25 to 30 kDa. The phosphorylation of this protein was also observed in response to SCF. This protein was identified as non-T-cell activation linker (NTAL), an adaptor molecule similar to linker for activated T cells (LAT). Unlike the Fc epsilon RI response, SCF induced NTAL phosphorylation in the absence of detectable LAT phosphorylation. When SCF and antigen were added concurrently, there was a marked synergistic effect on NTAL phosphorylation, however, SCF did not enhance the phosphorylation of LAT induced by Fc epsilon RI aggregation. Fc epsilon RI- and SCF-mediated NTAL phosphorylation appear to be differentially regulated by Src kinases and/or Kit kinase, respectively. Diminution of NTAL expression by silencing RNA oligonucleotides in HuMCs resulted in a reduction of both Kit- and Fc epsilon RI-mediated degranulation. NTAL, thus, appears to be an important link between the signaling pathways that are initiated by these receptors, culminating in mast cell degranulation.
Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.
Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo D Curr Allergy Asthma Rep. 2024; 24(2):63-71.
PMID: 38217824 DOI: 10.1007/s11882-023-01123-9.
Review and Updates on Systemic Mastocytosis and Related Entities.
Li J, Ryder C, Zhang H, Cockey S, Hyjek E, Moscinski L Cancers (Basel). 2023; 15(23).
PMID: 38067330 PMC: 10705510. DOI: 10.3390/cancers15235626.
Degranulation of Mast Cells as a Target for Drug Development.
Yang B, Kim A, Lee D, An S, Shim Y, Jang M Cells. 2023; 12(11).
PMID: 37296626 PMC: 10253146. DOI: 10.3390/cells12111506.
Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.
Dispenza M, Metcalfe D, Olivera A J Allergy Clin Immunol Pract. 2023; 11(7):2032-2042.
PMID: 36958519 PMC: 10330051. DOI: 10.1016/j.jaip.2023.03.015.
Drug delivery targets and strategies to address mast cell diseases.
Rische C, Thames A, Krier-Burris R, OSullivan J, Bochner B, Scott E Expert Opin Drug Deliv. 2023; 20(2):205-222.
PMID: 36629456 PMC: 9928520. DOI: 10.1080/17425247.2023.2166926.